Pfizer Boosts Rare Disease Franchise through Bamboo Therapeutics Acquisition
By Jasmine Kalsi
Pharma Deals Review: Vol 2016 Issue 8 (Table of Contents)
Published: 17 Aug-2016
DOI: 10.3833/pdr.v2016.i8.2184 ISSN: 1756-7874
Section: Mergers & Acquisitions
Fulltext:
Abstract
Fortifying its orphan disease portfolio with gene therapies, Pfizer acquired US based private biotech Bamboo Therapeutics for a consolidated sum of up to US$645 M, including US$150 M upfront and US$495 M in contingent milestones...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS